Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

First effective drug for sleep disorder identified

05.06.2003


In a clinical trial conducted at the University of Illinois at Chicago, researchers have demonstrated the first promising drug treatment for a common and life-threatening sleep disorder called sleep apnea.



The drug, an antidepressant called mirtazapine, significantly reduced the symptoms of sleep apnea. It cut in half the number of times breathing stopped or slowed during sleep and reduced the number of times sleep was disrupted by 28 percent. All 12 patients who participated in the study showed improvement.

"The drug provided the largest benefit and the most consistent improvement of any pharmaceutical therapy tested in controlled studies to date," said David Carley, professor of medicine, pharmacology and bioengineering and director of research at the UIC Center for Sleep and Ventilatory Disorders.


The results of the trial will be presented this week at the annual meeting of the Associated Professional Sleep Societies in Chicago by Carley and co-investigator Dr. Miodrag Radulovacki, professor of pharmacology and medicine at UIC.

"This has real clinical significance," said Radulovacki. "An estimated 15-20 million people in the United States suffer from sleep apnea, yet there is currently no cure and no fully effective long-term treatment for the disorder."

Apnea -- which means "without breath" -- is diagnosed when a person periodically stops breathing for 10 seconds or more or has episodes of reduced breathing during sleep. People suffering from sleep apnea may stop breathing hundreds of times a night, often for a minute or longer. The disorder is associated with increased risk of high blood pressure, heart attack, stroke and adult-onset diabetes. Behavioral problems and cognitive impairments can occur due to insufficient rest.

At present, sleep apnea is treated with mechanical devices, most often masks or nasal prongs, that maintain a continuous positive airway pressure. Such devices are uncomfortable, however, and difficult to use long-term.

The 12 patients in the UIC study were between the ages of 20 and 70. They received one of two dosages of mirtazapine or a placebo an hour before bedtime. They were monitored throughout the night in the UIC Center for Sleep and Ventilatory Disorders after each of three seven-day treatment periods.

The clinical trial at UIC followed years of laboratory tests of several classes of medications on a strain of rats that exhibit sleep apneas similar to the human disorder. Mirtazapine showed the most promise; other drugs either improved the condition only marginally or made it worse.

Mirtazapine blocks the activity of a chemical in the nervous system called serotonin that is involved in regulating mood, emotion, appetite and sleep.

The UIC study was funded by NV Organon, which markets mirtazapine as Remeron for the treatment of depression.

Mirtazapine has not been approved by the U.S. Food and Drug Administration for the treatment of sleep apnea. Its use in this trial was approved by a UIC institutional review board for experimental purposes only.

Sharon Butler | EurekAlert!
Further information:
http://www.uic.edu/

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>